News | Cardiac Diagnostics | August 27, 2018

Acarix Presents CADScor System at ESC 2018

Non-invasive, radiation-free device delivers high-sensitivity and -specificity assessment of coronary artery disease risk in less than 10 minutes

Acarix Presents CADScor System at ESC 2018

August 27, 2018 — Acarix AB’s ultra-sensitive acoustic CADScor System for coronary artery disease risk assessment will be on display at the European Society of Cardiology (ESC) Congress 2018, Aug. 25-28 in Munich, Germany. The CADScor System has been validated clinically to rule out CAD with 96-97 percent negative predictive value. The device is gaining interest and increased use across Germany and Denmark, key Swedish hospitals are testing the system and expansion in other European countries is under way. At ESC 2018, both in the exhibition booth and at a special session Aug. 28, there will be opportunities to get first-hand information about the CADScor System and to meet experts with experience from using the system in clinical practice.

The low diagnostic yield of current non-invasive testing in patients with suspected coronary artery disease has recently been described by Christina Therming et al.1 for a large hospital-based sample. Acarix CADScor System has been developed to add a reliable and simple diagnostic aid to the non-invasive diagnostic landscape that is easy to handle as a first line test in each clinical setting. The system is noninvasive, radiation-free and delivers a result in less than 10 minutes.

At ESC, visitors will hear how the performance of the CADScor System has recently been further documented. The system’s Algorithm v3 database contains 2,260 patients and performs with a sensitivity of 88.7 percent, specificity of 53.5 percent and a negative predictive value (NPV) of 95.9 percent for diagnosing CAD (stenosis >50 percent) versus non-CAD (stenosis < 30 percent). The NPV is 97.2 percent for diagnosing CAD (stenosis >50 percent) versus non-obstructive CAD (stenosis >30-< 50 percent) plus non-CAD (stenosis < 30 percent) (publication in preparation). Furthermore, a new study, Dan-NICAD II, is ongoing involving 1,500-2,000 patients with a low-to-intermediate likelihood of CAD from four Danish hospitals. The results are expected to further improve the CADScor System‘s already high NPV, to include patients aged < 40 years and to provide health economic documentation supporting its use as a fast and safe frontline assessment to reduce patient referrals.

For more information: www.acarix.com

Reference

1. Therming C., Galatius S., Heitmann M., et al. Low diagnostic yield of non-invasive testing in patients with suspected coronary artery disease: results from a large unselected hospital-based sample. European Heart Journal - Quality of Care and Clinical Outcomes, Dec. 18, 2017. https://doi.org/10.1093/ehjqcco/qcx048

Related Content

Insomnia Tied to Higher Risk of Heart Disease and Stroke

Image courtesy of the American Heart Association

News | Cardiac Diagnostics | August 19, 2019
People suffering from insomnia may have an increased risk of coronary artery disease, heart failure and stroke,...
Evolutionary Gene Loss May Help Explain Human Predisposition to Heart Attacks
News | Cardiac Diagnostics | July 29, 2019
The loss of a single gene two to three million years ago in our ancestors may have resulted in a heightened risk of...
U.S. Soldiers Have Worse Heart Health Than Civilians
News | Cardiac Diagnostics | June 06, 2019
Active duty Army personnel have worse cardiovascular health compared to people of similar ages in the civilian...
Late Dinner and No Breakfast Worsens Outcomes After Heart Attack
News | Cardiac Diagnostics | May 23, 2019
People who skip breakfast and eat dinner near bedtime have worse outcomes after a heart attack, according to research...
HRS Releases New Expert Consensus Statement on Arrhythmogenic Cardiomyopathy
News | Cardiac Diagnostics | May 14, 2019
The Heart Rhythm Society (HRS) released a first-of-its-kind consensus statement with guidance on the evaluation and...
New Best Practices Help Manage Heart Attack Patients Without Significant Signs
News | Cardiac Diagnostics | April 15, 2019
For the first time in the United States, doctors with the American Heart Association (AHA) have outlined best practices...
The most recent U.S. Food and Drug Administration (FDA) clearance was Siemens Healthineers high-sensitivity troponin I assays (TnIH) for the Atellica IM and ADVIA Centaur XP/XPT in vitro diagnostic analyzers. The test helps in the early diagnosis of myocardial infarctions without the need for serial tropic testing. The time to first results is 10 minutes.

The most recent U.S. Food and Drug Administration (FDA) clearance was Siemens Healthineers high-sensitivity troponin I assays (TnIH) for the Atellica IM and ADVIA Centaur XP/XPT in vitro diagnostic analyzers. The test helps in the early diagnosis of myocardial infarctions without the need for serial tropic testing. The time to first results is 10 minutes. 

Feature | Cardiac Diagnostics | March 22, 2019 | Linda C. Rogers, Ph.D.
Troponins are a family of proteins found in skeletal and heart (cardiac) muscle fibers that produce muscular contract
ACC/AHA Update Guidance for Preventing Heart Disease; Stroke
Feature | Cardiac Diagnostics | March 18, 2019
The choices we make every day can have a lasting effect on our heart and vascular health. Adopting a heart healthy...
AHA Statement Warns Hookah Smoking May Harm the Heart
News | Cardiac Diagnostics | March 08, 2019
Smoking tobacco in waterpipes, more commonly known as hookahs, results in inhaling toxic chemicals, often at levels...
Overlay Init